Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

JW to Start China Trials of CAR-T for Pediatric/Young Adult Leukemia

publication date: Apr 20, 2022

JW Therapeutics, a Shanghai CAR-T company, will start China trials of Carteyva®, its anti-CD19 CAR-T therapy, in pediatric and young adult patients. In September 2021, the CAR-T was approved in China as a third-line therapy for adult patients with B-cell lymphoma. The new trial will enroll young patients with relapsed or refractory lymphoblastic leukemia. JW was formed in 2018 as a JV between Juno Therapeutics of Seattle and WuXi AppTec. It now calls itself an independent company. More details....

Stock Symbol: (HK: 2126)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital